• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Microbes and Infectious Diseases
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 3 (2022)
Volume Volume 2 (2021)
Volume Volume 1 (2020)
Said, N., Walaa, M., Gamal, D., Amer, R., Ahmed, A. (2022). Antibody responses to acute COVID-19 infection; assessment via multiplex LABScreen COVID Plus Assay. Microbes and Infectious Diseases, (), -. doi: 10.21608/mid.2022.138557.1315
Nora M. Said; Mohammad Walaa; Dina Gamal; Rania Amer; Alshymaa A. Ahmed. "Antibody responses to acute COVID-19 infection; assessment via multiplex LABScreen COVID Plus Assay". Microbes and Infectious Diseases, , , 2022, -. doi: 10.21608/mid.2022.138557.1315
Said, N., Walaa, M., Gamal, D., Amer, R., Ahmed, A. (2022). 'Antibody responses to acute COVID-19 infection; assessment via multiplex LABScreen COVID Plus Assay', Microbes and Infectious Diseases, (), pp. -. doi: 10.21608/mid.2022.138557.1315
Said, N., Walaa, M., Gamal, D., Amer, R., Ahmed, A. Antibody responses to acute COVID-19 infection; assessment via multiplex LABScreen COVID Plus Assay. Microbes and Infectious Diseases, 2022; (): -. doi: 10.21608/mid.2022.138557.1315

Antibody responses to acute COVID-19 infection; assessment via multiplex LABScreen COVID Plus Assay

Articles in Press, Accepted Manuscript, Available Online from 15 June 2022  XML
Document Type: Original Article
DOI: 10.21608/mid.2022.138557.1315
Authors
Nora M. Said1; Mohammad Walaa2; Dina Gamal1; Rania Amer email orcid 3; Alshymaa A. Ahmedorcid 1
1Clinical Pathology Department, Faculty of Medicine, Zagazig University
2Chest Department, Faculty of Medicine, Zagazig University
3Medical Microbiology and Immunology department, Faculty of Medicine and Scientific and Medical Research Center, Zagazig University
Abstract
Background: Understanding the profile of antibody responses following acute COVID-19 infection is required. Aim: to describe the pattern of IgG anti-COVID-19 antibody production in patients with acute infection using the LABScreen COVID Plus assay. Results: The overall seropositivity was 69/73(94.5%). Anti-Spike, Spike 1 and spike S2 subunit were positive in 78.1%, while anti spike Receptor binding domain (RBD) was detected in 68.4% and anti nucleocapsid protein in 61.6%. The overall positivity of the assay reached 100.0% during the second week post symptoms. The mean fluorescent intensities (MFI) of anti-Spike S1 was higher in the second week than the first week, P=0.03. MFI of anti-Spike S2 was significantly higher in PCR positive patients in comparison with the negative ones, p=0.006. When compared to the RT-PCR results; the overall antibodies positivity, anti-Spike, and anti-Spike2 antibodies had sensitivities (100% and 84.7%) and specificities (28.6% and 50.0%) and accuracies (86.3% and 78.1%). Patients' outcome correlated significantly with the time of hospital admission, P=0.001. Conclusions: COVID-19 IgG antibodies are detectable with considerable frequencies during the first two weeks post infection. Anti S2 antibodies correlates well with the RT-PCR results. The LABScreen COVID Plus is a sensitive assay for the detection of post-acute COVID-19 infection antibody responses.
Keywords
Antibodies; COVID-19; performance; real-time PCR; sensitivities
Main Subjects
Infectious diseases
Statistics
Article View: 19
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.